Trials / Completed
CompletedNCT02516046
18F-AV-1451 Autopsy Study
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | 370 megabecquerel (MBq) IV single-dose |
| PROCEDURE | PET Scan | positron emission tomography (PET) scan |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2018-06-13
- Completion
- 2018-07-15
- First posted
- 2015-08-05
- Last updated
- 2020-09-07
- Results posted
- 2020-09-07
Locations
31 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02516046. Inclusion in this directory is not an endorsement.